A detailed history of Royal Bank Of Canada transactions in Precigen, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 12,714 shares of PGEN stock, worth $11,442. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,714
Previous 18,766 32.25%
Holding current value
$11,442
Previous $29,000 58.62%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.91 - $1.88 $5,507 - $11,377
-6,052 Reduced 32.25%
12,714 $12,000
Q2 2024

Aug 14, 2024

BUY
$1.27 - $1.75 $18,807 - $25,915
14,809 Added 374.25%
18,766 $29,000
Q1 2024

Nov 05, 2024

SELL
$1.21 - $1.75 $17,918 - $25,915
-14,809 Reduced 78.91%
3,957 $5,000
Q1 2024

May 15, 2024

SELL
$1.21 - $1.75 $44,714 - $64,669
-36,954 Reduced 90.33%
3,957 $5,000
Q4 2023

Feb 14, 2024

SELL
$0.89 - $1.41 $129,160 - $204,624
-145,124 Reduced 78.01%
40,911 $54,000
Q3 2023

Nov 14, 2023

BUY
$1.08 - $1.85 $184,917 - $316,757
171,220 Added 1155.72%
186,035 $264,000
Q2 2023

Aug 14, 2023

BUY
$0.96 - $1.4 $5,688 - $8,295
5,925 Added 66.65%
14,815 $17,000
Q1 2023

May 15, 2023

SELL
$0.88 - $2.19 $2,733 - $6,802
-3,106 Reduced 25.89%
8,890 $9,000
Q4 2022

Feb 14, 2023

BUY
$1.27 - $2.26 $10,979 - $19,537
8,645 Added 257.98%
11,996 $18,000
Q3 2022

Nov 14, 2022

BUY
$1.41 - $2.79 $513 - $1,015
364 Added 12.19%
3,351 $7,000
Q2 2022

Aug 15, 2022

SELL
$1.15 - $2.53 $10,122 - $22,269
-8,802 Reduced 74.66%
2,987 $4,000
Q1 2022

May 16, 2022

SELL
$1.91 - $3.98 $96,042 - $200,130
-50,284 Reduced 81.01%
11,789 $24,000
Q4 2021

Feb 14, 2022

SELL
$3.53 - $5.5 $5,199 - $8,101
-1,473 Reduced 2.32%
62,073 $230,000
Q3 2021

Nov 15, 2021

BUY
$4.99 - $6.55 $192,289 - $252,404
38,535 Added 154.07%
63,546 $318,000
Q2 2021

Aug 16, 2021

BUY
$6.24 - $8.22 $156,068 - $205,590
25,011 New
25,011 $163,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $187M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.